title: Correlation between expression of CD56/NCAM and severe leukostasis in hyperleukocytic acute myelomonocytic leukaemia.
abstract: OBJECTIVE
  The possible contribution of surface molecules to the development of leukostasis syndrome in hyperleukocytic acute myeloid leukaemia (AML) was assessed by routine immunophenotyping and grading of the probability of clinical leukostasis.
  
  
  METHODS
  Fifty-three patients (23 women, 30 men, median age 59 yr) with hyperleukocytic AML [white blood count (WBC) above 50 x 10(9)/L] were graded for the probability of clinical leukostasis according to the severity of neurologic, pulmonary and other symptoms possibly caused by leukostasis using a recently published scoring system. Age, WBC, absolute blast count, haemoglobin, cytogenetic risk group, infection, relative CD56 expression and absolute count of CD56 positive blasts were analyzed in multivariate stepwise backward logistic regression analysis.
  
  
  RESULTS
  In patients with acute monocytic leukaemia (AML M4/M5) the absolute count of leukaemic blasts expressing CD56/NCAM was highly associated with the development of symptoms graded as highly probable leukostasis and all three patients succumbing to early death were CD56 positive. Only the absolute count of CD56 positive blasts was a significant predictor of risk of severe leukostasis (P = 0.020). This was not found in AML without monocytic involvement (AML M1, M2, M3v).
  
  
  CONCLUSIONS
  The expression of CD56/NCAM, a surface marker used in routine immunophenotyping of AML, may help to predict severe and potentially fatal leukostasis in hyperleukocytic acute myelomonocytic leukaemia. These results emphasize the usefulness of this four-stage clinical grading scale for analysing the factors, which lead to severe leukostasis in hyperleukocytic patients. We extend previous findings that the mechanisms of leukostasis are different depending on the involvement of the monocytic lineage.
authors.affiliation: Department of Haematology, University Hospital of Essen, Essen, Germany. juergen.novotny@medizin.uni-essen.de
authors.forename: J R
authors.initials: JR
authors.lastname: Novotny
authors.forename: H
authors.initials: H
authors.lastname: Nückel
authors.forename: U
authors.initials: U
authors.lastname: Dührsen
mesh_terms: D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D019002:CD56 Antigen / Q000097:blood*; D005260:Female; D015973:Gene Expression Regulation, Leukemic; D006801:Humans; D016130:Immunophenotyping / Q000379:methods; D015479:Leukemia, Myelomonocytic, Acute / Q000097:blood* / Q000150:complications / Q000401:mortality; D007958:Leukocyte Count / Q000379:methods; D018921:Leukostasis / Q000097:blood* / Q000150:complications / Q000401:mortality; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging / Q000379:methods / Q000401:mortality; D012307:Risk Factors; D012720:Severity of Illness Index
chemical_list: D019002:CD56 Antigen